In the trial, aldoxorubicin showed prolonged clinical activity, including partial tumor response, in two subjects with small-cell lung cancer who had failed other therapies
Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it reached agreement with the FDA on a Phase III registration trial of lead immunotherapeutic candidate bavituximab in second-line non-small-cell lung cancer (NSCLC
Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, reported data from two Phase III trials involving two investigational oncology compounds – afatinib and nintedanib – in two distinct patient populations with advanced non-small-cell lung cancer (NSCLC
Complete and partial radiological remissions were observed in patients with small-cell lung, bladder, breast, endometrial and ovarian cancers, neuroendocrine tumors and synovial sarcoma...The company is planning a potential pivotal trial in small-cell lung cancer and a confirmatory activity trial in endometrial cancer
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., reported that the last patient has been enrolled in the first cohort of a randomized Phase II trial of MM-121 in combination with erlotinib for the treatment of non-small-cell lung cancer (NSCLC
OncoGenex Pharmaceuticals Inc., of Vancouver, British Columbia, said an investigator-sponsored, randomized, double-blind, placebo-controlled Phase II trial of OGX-427 in non-small-cell lung cancer (NSCLC) will be initiated to evaluate whether the drug in combination with carboplatin and pemetrexed can extend progression-free survival
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said one cohort of a Phase II non-small-cell lung cancer (NSCLC) study did not meet its primary endpoint
Axelar AB, of Stockholm, Sweden, part of the Karolinska Development AB portfolio, reported preliminary interim results from its Phase II study of AXL1717, indicating that the small-molecule IGF-1 receptor inhibitor is effective in treating patients with non-small-cell lung cancer
Biothera Inc., of Eagen, Minn., said it completed enrollment of its 90-patient Phase IIb study testing Imprime PGG, Avastin (bevacizumab, Roche AG) and two chemotherapeutic drugs in non-small-cell lung cancer
Oncolytics Biotech Inc., of Calgary, Alberta, said it completed patient enrollment in a Phase II trial testing intravenous administration of oncolytic virus candidate Reolysin in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer with KRAS or EGFR-activated tumors
Endocyte Inc., of San Diego, said a new analysis demonstrated that the investigational diagnostic imaging agent etarfolatide (EC20) can identify ovarian cancer and non-small-cell lung cancer (NSCLC) patients who could benefit from folate receptor-targeted therapeutics, such as the investigational cancer candidate vintafolide (MK-8109/EC145
CytRx Corp., of Los Angeles, said it completed enrollment of 140 patients in its Phase IIb study testing oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment in advanced non-small-cell lung cancer
Peregrine Pharmaceuticals Inc., of Tustin, Calif., said updated data from its Phase II study testing bavituximab in patients with second-line non-small-cell lung cancer showed a meaningful improvement in median overall survival of 11 .7 months in the 3-mg/kg-bavituximab-plus-docetaxel arm vs. 7.3 months in the control arm (p = 0.217
ImmunoGen Inc., of Waltham, Mass., completed patient enrollment in the first stage of its NORTH Phase II trial assessing clinically meaningful benefit of IMGN901 in small-cell lung cancer...The company said studies designed to validate Kruppel-like factor 4 (KLF4) as a biomarker of LOR-253 activity demonstrated that tumor levels of KLF4 increased with anticancer activity of LOR-253 in animal models of human non-small-cell lung cancer
Nektar Therapeutics Inc., of San Francisco, said it started a Phase II study of etirinotecan pegol in patients with metastatic and recurrent non-small-cell lung cancer
Cerulean Pharma Inc., of Cambridge, Mass., said the first patient was dosed in a Phase II study of CRLX101, a nanopharmaceutical designed to inhibit both topoisomerase 1 and hypoxia-inducible factor-1 alpha, in extensive-stage small-cell lung cancer sensitive to first-line platinum-based chemotherapy...CytRx Corp., of Los Angeles, said a data safety monitoring committee recommended continuing a Phase IIb trial of tamibarotene with chemotherapy in non-small-cell lung cancer
In the trial, aldoxorubicin showed prolonged clinical activity, including partial tumor response, in two subjects with small-cell lung cancer who had failed other therapies